
Agnieszka Czarniecka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7779135/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3228-3238.	1.8	36
2	Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma – Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015. Frontiers in Endocrinology, 2021, 12, 718833.	1.5	1
3	Definitive treatment of Graves' disease in children and adolescents. Endokrynologia Polska, 2021, 72, 661-665.	0.3	2
4	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. European Journal of Cancer, 2020, 124, 161-169.	1.3	41
5	TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma. Cancers, 2020, 12, 1597.	1.7	13
6	Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma—Do They Exist?. International Journal of Molecular Sciences, 2020, 21, 4629.	1.8	5
7	Impact of the Tumor Microenvironment on the Gene Expression Profile in Papillary Thyroid Cancer. Pathobiology, 2020, 87, 143-154.	1.9	8
8	Heterogeneity of Thyroid Cancer. Pathobiology, 2018, 85, 117-129.	1.9	117
9	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. Journal of the National Cancer Institute, 2018, 110, 362-370.	3.0	60
10	Patient Age–Associated Mortality Risk Is Differentiated by <i>BRAF</i> V600E Status in Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 438-445.	0.8	102
11	<i>BRAF</i> V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 2787-2795.	0.8	58
12	Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients. International Journal of Molecular Sciences, 2018, 19, 2647.	1.8	37
13	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3241-3250.	1.8	80
14	Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?. International Journal of Molecular Sciences, 2017, 18, 1817.	1.8	34
15	Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours. International Journal of Molecular Sciences, 2017, 18, 1184.	1.8	32
16	BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surgery, 2016, 5, 495-505.	0.5	58
17	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	1.8	179
18	The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors. PLoS ONE, 2015, 10, e0132821.	1.1	31

#	Article	IF	CITATIONS
19	Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid Cancer. Journal of Clinical Oncology, 2015, 33, 42-50.	0.8	448
20	BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma. PLoS ONE, 2015, 10, e0143688.	1.1	49
21	Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers – the role of Ct serum level. Thyroid Research, 2013, 6, S9.	0.7	14
22	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 1493.	3.8	775
23	External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement. Laryngoscope, 2013, 123, S1-14.	1.1	263
24	Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues. BMC Medical Genomics, 2013, 6, 38.	0.7	28
25	Unsupervised analysis of follicular thyroid tumours transcriptome by oligonucleotide microarray gene expression profiling. Endokrynologia Polska, 2013, 64, 328-334.	0.3	3
26	Prognostic value of lymph node metastases of differentiated thyroid cancer (DTC) according to the local advancement and range of surgical excision. Thyroid Research, 2010, 3, 8.	0.7	9
27	Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Molecular and Cellular Endocrinology, 2010, 322, 8-28.	1.6	114
28	Occurrence of BRAF mutations in a Polish cohort of PTC patients - preliminary results. Endokrynologia Polska, 2010, 61, 462-6.	0.3	10
29	Gene Expression Profile of Papillary Thyroid Cancer: Sources of Variability and Diagnostic Implications. Cancer Research, 2005, 65, 1587-1597.	0.4	238
30	European perspective on active surveillance for papillary thyroid microcarcinoma—are we ready?. Annals of Thyroid, 0, 5, 15-15.	1.0	1